Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review

Sameer Dhayat; Wolf Arif Mardin; Soeren Torge Mees; Joerg Haier

doi:10.1002/ijc.26078

Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review

Standard

Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review. / Dhayat, Sameer; Mardin, Wolf Arif; Mees, Soeren Torge; Haier, Joerg.

in: INT J CANCER, Jahrgang 129, Nr. 5, 01.09.2011, S. 1031-41.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Dhayat, S, Mardin, WA, Mees, ST & Haier, J 2011, 'Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review', INT J CANCER, Jg. 129, Nr. 5, S. 1031-41. https://doi.org/10.1002/ijc.26078

APA

Dhayat, S., Mardin, W. A., Mees, S. T., & Haier, J. (2011). Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review. INT J CANCER, 129(5), 1031-41. https://doi.org/10.1002/ijc.26078

Vancouver

Dhayat S, Mardin WA, Mees ST, Haier J. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review. INT J CANCER. 2011 Sep 1;129(5):1031-41. https://doi.org/10.1002/ijc.26078

Bibtex

@article{b0153bf337a846e2b54b384e61f1056f,

title = "Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review",

abstract = "Adjuvant first-line gemcitabine monochemotherapy presents a standard treatment for patients with advanced pancreatic adenocarcinoma and improves overall survival in chemosensitive patients. Nonetheless, 6-month progression-free survival remains below 15%, despite interdisciplinary approaches. The success of gemcitabine treatment is disappointing and-in the absence of reliable tumor markers--challenging to quantify. Epigenetic alterations have been recently identified to take on important roles in cancer development and possibly cancer treatment. In this context, microRNAs are becoming increasingly acknowledged as useful biomarkers for classifying cancers and providing information on their chemo- and radiosensitivity. This review illustrates the potential of genetic and epigenetic markers in the prediction of chemosensitivity in pancreatic cancer patients and in the monitoring of their response rates to adjuvant therapy.",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Drug Resistance, Neoplasm, Humans, Pancreatic Neoplasms",

author = "Sameer Dhayat and Mardin, {Wolf Arif} and Mees, {Soeren Torge} and Joerg Haier",

note = "Copyright {\textcopyright} 2011 UICC.",

year = "2011",

month = sep,

day = "1",

doi = "10.1002/ijc.26078",

language = "English",

volume = "129",

pages = "1031--41",

journal = "INT J CANCER",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "5",

}

RIS

TY - JOUR

T1 - Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review

AU - Dhayat, Sameer

AU - Mardin, Wolf Arif

AU - Mees, Soeren Torge

AU - Haier, Joerg

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Adjuvant first-line gemcitabine monochemotherapy presents a standard treatment for patients with advanced pancreatic adenocarcinoma and improves overall survival in chemosensitive patients. Nonetheless, 6-month progression-free survival remains below 15%, despite interdisciplinary approaches. The success of gemcitabine treatment is disappointing and-in the absence of reliable tumor markers--challenging to quantify. Epigenetic alterations have been recently identified to take on important roles in cancer development and possibly cancer treatment. In this context, microRNAs are becoming increasingly acknowledged as useful biomarkers for classifying cancers and providing information on their chemo- and radiosensitivity. This review illustrates the potential of genetic and epigenetic markers in the prediction of chemosensitivity in pancreatic cancer patients and in the monitoring of their response rates to adjuvant therapy.

AB - Adjuvant first-line gemcitabine monochemotherapy presents a standard treatment for patients with advanced pancreatic adenocarcinoma and improves overall survival in chemosensitive patients. Nonetheless, 6-month progression-free survival remains below 15%, despite interdisciplinary approaches. The success of gemcitabine treatment is disappointing and-in the absence of reliable tumor markers--challenging to quantify. Epigenetic alterations have been recently identified to take on important roles in cancer development and possibly cancer treatment. In this context, microRNAs are becoming increasingly acknowledged as useful biomarkers for classifying cancers and providing information on their chemo- and radiosensitivity. This review illustrates the potential of genetic and epigenetic markers in the prediction of chemosensitivity in pancreatic cancer patients and in the monitoring of their response rates to adjuvant therapy.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biomarkers, Tumor

KW - Drug Resistance, Neoplasm

KW - Humans

KW - Pancreatic Neoplasms

U2 - 10.1002/ijc.26078

DO - 10.1002/ijc.26078

M3 - SCORING: Journal article

C2 - 21413017

VL - 129

SP - 1031

EP - 1041

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 5

ER -